TY - JOUR
T1 - Economic assessment of eltrombopag in the treatment of thrombocytopenia
AU - Romano, Federica
AU - Ruggeri, Matteo
AU - Coretti, Silvia
AU - Giannini, Edoardo Giovanni
AU - Sacchini, Dario
AU - Annichiarico, Brigida Eleonora
AU - Marchetti, Marco
AU - Rodeghiero, Francesco
AU - Lidonnici, Dario
PY - 2015
Y1 - 2015
N2 - Objective: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. Methods: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. Results: Base case results demonstrate that scenario 1 is associated with a cost per QALY of e30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of e32,752.44 per QALY when scenario 1 is compared with scenario 3. Conclusion: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.
AB - Objective: This study assesses the cost-effectiveness of eltrombopag in the treatment of hepatitis C virus (HCV)-related thrombocytopenia. Methods: A Markov model was constructed on the basis of the clinical trials ENABLE 1 and ENABLE 2. Three alternatives were considered: scenario 1; treatment with eltrombopag in both the enabling phase and during antiviral therapy, as in the ENABLE trial design; scenario 2; no eltrombopag treatment and no antiviral therapy; scenario 3; no eltrombopag treatment and subsequent administration of a reduced dose of peg-IFN. Results: Base case results demonstrate that scenario 1 is associated with a cost per QALY of e30,020.94 in comparison with scenario 2. The incremental cost-effectiveness ratio reaches a value of e32,752.44 per QALY when scenario 1 is compared with scenario 3. Conclusion: The use of eltrombopag in HCV patients with thrombocytopenia is cost-effective as it leads to a reduction in disease progression and thus a drop in the number of patients with advanced liver disease.
KW - Cost-effectiveness
KW - Markov model
KW - Revolade
KW - Sensitivity analysis
KW - Thrombocytopenia
UR - http://www.scopus.com/inward/record.url?scp=84945948851&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84945948851&partnerID=8YFLogxK
U2 - 10.1586/14737167.2015.1028373
DO - 10.1586/14737167.2015.1028373
M3 - Article
C2 - 26176754
AN - SCOPUS:84945948851
VL - 15
SP - 713
EP - 720
JO - Expert Review of Pharmacoeconomics and Outcomes Research
JF - Expert Review of Pharmacoeconomics and Outcomes Research
SN - 1473-7167
IS - 4
ER -